Amuvatinib blocked SARS-CoV-2 infection in Vero E6 cells, with an EC50 of 0.36 μM determined by qRT-PCR. In U266 cells, Amuvatinib at 5 μM produced ~40% growth inhibition after 48 and 72 h of incubation. In LNCaP cells exposed to varying concentrations of Amuvatinib for 4 days, MTS analysis yielded an IC50 of ~4 μM. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Amuvatinib Inhibition of Viral Infection in Vero Cells
Cell-based study · Vero E6 cells [1]
Vero E6 cells were exposed to various concentrations of Amuvatinib. Amuvatinib blocked SARS-CoV-2 infection, with an EC50 of 0.36 μM determined by qRT-PCR.
Literature-Reported Treatment Conditions
- Exposure duration
- for 1 h; further cultured in fresh media containing amuvatinib; At 24 h postinfection
- Method
- in the absence or presence of various concentrations of amuvatinib
- Co-treatment
- Other interventions in this design: SARS-CoV-2 MOI = 0.01. Compound effect isolated by the comparison: in the absence or presence of various concentrations of amuvatinib.
- Reported limits
- Not stated in the sentences used: dose, vehicle.
Methods and source locations
Compound reported in the paper: Amuvatinib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > Characterization of amuvatinib as an anti-SARS-CoV-2 agent. (S22); FIG 2 legend (S142, S143, S146, S147)
the EC50 value was determined by qRT-PCR: the EC50 value was determined by qRT-PCR; comparator: in the absence or presence of various concentrations of amuvatinib — RESULTS > Characterization of amuvatinib as an anti-SARS-CoV-2 agent. (S22); FIG 2 legend (S147)
Amuvatinib Growth Inhibition in Myeloma Cells
Cell-based study · U266 cells [2]
U266 cells were treated with Amuvatinib at 5 μM. Growth inhibition was ~40% after 48 and 72 h of incubation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM
- Exposure duration
- 48 and 72 h of incubation
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Amuvatinib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Effect of Amuvatinib on Growth Inhibition (S28, S29); Methods > Materials (S89); Methods > Cell culture and growth analysis (S102)
cell growth inhibition: cell growth inhibition; comparator: DMSO-treated control cells — Results > Effect of Amuvatinib on Growth Inhibition (S29); Methods > Cell culture and growth analysis (S102)
Amuvatinib Effects on LNCaP Cell Viability
Cell-based study · LNCaP [3]
LNCaP cells were exposed to varying concentrations of Amuvatinib for 4 days. Cell viability assessed by MTS analysis yielded an IC50 of ~4 μM.
Literature-Reported Treatment Conditions
- Treatment concentration
- varying concentrations
- Exposure duration
- for 4 days
- Method
- exposed to varying concentrations of MP470
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: control.
Methods and source locations
Compound reported in the paper: Amuvatinib; Compound label in the paper: MP470
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Cells and reagents (S7); Results > MP470 alone or in combination with Erlotinib inhibits prostate cancer cell proliferation, promotes cell cycle arrest and apoptosis (S77); Figure 1 legend (S131, S132, S134)
Cell viability was assessed by MTS analysis.: Cell viability was assessed by MTS analysis. — Results > MP470 alone or in combination with Erlotinib inhibits prostate cancer cell proliferation, promotes cell cycle arrest and apoptosis (S77); Figure 1 legend (S132, S134)